AURION BIOTECH

Transformational Cell Therapy

Greg Kunst, CEO

Highlights: Transformational Cell Therapy

$9B Market
- Corneal endothelial disease
- Large unmet need: 1 donor for every 70 diseased eyes

Regulatory Momentum
- Japan: approved 1H 23
  - Commercial launch 2H 24
- US: Phase 1 / 2 dosing complete (2Q 24)

Manufacturing Advantages
- "Pharma-like" margins (>90%)
- High scale: 1 donor → 31000 doses

Clinical Validation
- >130 subjects treated to date

Strong Financial Backing
- $132M raised from top-tier investors

Experienced Team
Novartis, Glaukos, Alcon, Ocular Therapeutix, SeaGen

AURN001: Combination Drug Product

Human Corneal Endothelial Cells (HCECs) + Rho Kinase Inhibitor (Small Molecule)

- Fully differentiated, allogeneic human corneal endothelial cells (HCECs)
  - No donor matching required
  - No gene engineering
- Single dose, intracameral administration (HCECs + rho kinase inhibitor)
  - Biologic: HCECs restore vision
  - Small molecule: rho kinase inhibitor enables rapid cell engraftment
- Durable, accessible procedure
  - Available to larger pool of HCPs (cataract / anterior segment surgeons, general ophthalmologists)

Endothelial Cell Therapy Manufacture – How It Works

Proprietary Cell Replication Technology: Cells from Single Donor Can Treat **1,000** Eyes

1



- Transplantation-grade donor cornea as starting material
- Corneal endothelial cells (CECs) are isolated

2



- Donor CECs are introduced to proprietary culture and propagation begins

3



- CECs are manufactured to produce 1,000 doses

First 11 Subjects Treated in Japan

Long-Term Safety & Efficacy

Ophthalmology

The NEW ENGLAND JOURNAL of MEDICINE

Exploratory Endpoints	Pre-op	6 Months	2 Years	5 Years	Healthy Range[1]
Mean Corneal Thickness (µm)	743	549	552	555	540 - 555
Mean Visual Acuity (Snellen)	20/220	20/33	20/23	20/30	20/20 – 20/40
Safety / Tolerability	N/A	No SAE	No SAE	No SAE	N/A

Source:
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810328/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545036/#!po=8.33333

Multi-Study Efficacy Analysis

Consistency of Improvement in Corneal Thickness (CCT) Across Japan & El Salvador Trials



Bars display Standard Error

Multi-Study Efficacy Analysis

High Proportion of 3-Line Responders in Visual Acuity (BCVA) Across Trials



Japan: N=65
IOTA-1: N=16
Escalón: N=22

Bars display Standard Error